Abstract
Antibody-directed enzyme prodrug therapy aims to restrict the action of a cytotoxic drug to cancer sites. An enzyme that has no human analogue is delivered to cancer sites by attachment to an antibody directed at a tumour associated antigen. In a second step an antibody or other agent inactivates and clears enzyme from blood. The third step is administration of a low toxicity prodrug that is a substrate for the enzyme thus generating a potent cytotoxic agent at cancer sites. Encouraging results were obtained with this system in small scale clinical trials using unrefined agents. During the past 10 years attempts have been made to reduce the system to two components. Although these have met with some success it is now accepted that future progress requires all three components.
Keywords: ADEPT, antibody, enzyme, prodrug, fusion proteins, cancer therapy
Current Drug Targets
Title: Targeting: The ADEPT Story So Far
Volume: 10 Issue: 2
Author(s): K. D. Bagshawe
Affiliation:
Keywords: ADEPT, antibody, enzyme, prodrug, fusion proteins, cancer therapy
Abstract: Antibody-directed enzyme prodrug therapy aims to restrict the action of a cytotoxic drug to cancer sites. An enzyme that has no human analogue is delivered to cancer sites by attachment to an antibody directed at a tumour associated antigen. In a second step an antibody or other agent inactivates and clears enzyme from blood. The third step is administration of a low toxicity prodrug that is a substrate for the enzyme thus generating a potent cytotoxic agent at cancer sites. Encouraging results were obtained with this system in small scale clinical trials using unrefined agents. During the past 10 years attempts have been made to reduce the system to two components. Although these have met with some success it is now accepted that future progress requires all three components.
Export Options
About this article
Cite this article as:
Bagshawe D. K., Targeting: The ADEPT Story So Far, Current Drug Targets 2009; 10 (2) . https://dx.doi.org/10.2174/138945009787354520
DOI https://dx.doi.org/10.2174/138945009787354520 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Engagement of Renin-Angiotensin System in Prostate Cancer
Current Cancer Drug Targets Targeting Nodal and Cripto-1: Perspectives Inside Dual Potential Theranostic Cancer Biomarkers
Current Medicinal Chemistry The Characteristics, Functions and Inhibitors of Three Aminopeptidases Belonging to the M1 Family
Current Protein & Peptide Science Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects
Current Pharmaceutical Design Oncogenic Signaling Pathways Activated by RON Receptor Tyrosine Kinase
Current Cancer Drug Targets Erythropoietin in Cancer: An Update
Current Molecular Medicine Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems
Current Medicinal Chemistry 7-O-aminoalkyl-2,3-dehydrosilibinins: Synthesis and in vitro Anti-cancer Efficacy
Anti-Cancer Agents in Medicinal Chemistry Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
Mini-Reviews in Medicinal Chemistry Effects of Vitamin E and C on Placental Oxidative Stress: An In Vitro Evidence for the Potential Therapeutic or Prophylactic Treatment of Preeclampsia
Medicinal Chemistry MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets Surgical Strategies for Fertility Preservation in Women with Cancer
Current Women`s Health Reviews Recent Patents on Glioblastoma Signaling
Recent Patents on Biomarkers Angiogenic and Vascular Modulation by Extracellular Matrix Cleavage Products
Current Pharmaceutical Design Modified Envelope Glycoproteins to Retarget Retroviral Vectors
Current Gene Therapy Blockade of Neoangiogenesis, a New and Promising Technique to Control the Growth of Malignant Tumors and their Metastases
Current Vascular Pharmacology Synthesis, Biological Evaluation and Molecular Dynamics Simulation Studies of Novel Diphenyl Ethers
Medicinal Chemistry MicroRNA Polymorphisms, MicroRNA Pharmacogenomics and Cancer Susceptibility
Current Pharmacogenomics and Personalized Medicine Vertebrate Protein CTCF and its Multiple Roles in a Large-Scale Regulation of Genome Activity
Current Genomics The Role of Trophoblast Nutrient and Ion Transporters in the Development of Pregnancy Complications and Adult Disease
Current Vascular Pharmacology